JP Morgan Healthcare Conference
Exelixis Announces Corporate Restructuring, Layoffs, Details Pipeline Priorities
The firm will refocus its pipeline around clinical or near-clinical programs in 2024, while repurchasing common stock worth $450 million.
JP Morgan Healthcare Conference Day 4: Zymeworks, Solid Biosciences, and Carisma Therapeutics
On the fourth day of the conference, companies forecast plans for their precision medicine assets in 2024.
JP Morgan Healthcare Conference Day 3: Voyager, Precigen, Nykode, Grail, Myriad Genetics, Quanterix
On the third day, companies discussed progress on precision medicines for Alzheimer's and amyotrophic lateral sclerosis, CAR T therapies, cancer vaccines, and multi-cancer early detection tests.
Lexeo Therapeutics to Dose First Human in Arrhythmogenic Cardiomyopathy Gene Therapy Trial
The firm will dose the first patient in the trial of LX2020 in the first half of 2024, the CEO said at the JP Morgan Healthcare Conference.
JP Morgan Healthcare Conference Day 2: Bluebird Bio, Ideaya, Revolution, Relay, and More
On the second day, companies developing precision medicines and tests discussed pipeline priorities and strategic options for their businesses.